Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Cornelia Haag‐Molkenteller
Observed names:
C Haag-Molkenteller,
C. Haag-Molkenteller,
Cornelia Haag Molkenteller,
Cornelia Haag-Molkenteller
Institutions:
Clinical Research Consulting,
University of Pennsylvania
Observed institutions:
Clinical Research Consulting,
Allergan (United States),
Stadt Mannheim,
Urovant Sciences GmbH (Switzerland),
University of Pennsylvania
OpenAlex ID:
A5064768277
Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial
2011
·
Francisco Cruz
, Sender Herschorn
, et al.
·
European Urology
·
517
OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial
2013
·
Christopher Chapple
, Karl-Dietrich Sievert
, et al.
·
European Urology
·
456
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial
2012
·
Victor W. Nitti
, Roger Dmochowski
, et al.
·
The Journal of Urology
·
445
Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial
2010
·
Roger Dmochowski
, Christopher Chapple
, et al.
·
The Journal of Urology
·
417
Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor Overactivity
2012
·
David Ginsberg
, Angelo Gousse
, et al.
·
The Journal of Urology
·
374
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial
2016
·
Victor W. Nitti
, Roger Dmochowski
, et al.
·
The Journal of Urology
·
334
Epidemiology and healthcare utilization of neurogenic bladder patients in a us claims database
2010
·
Aubrey Manack
, Stephen P. Motsko
, et al.
·
Neurourology and Urodynamics
·
316
Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder
2007
·
Christopher Chapple
, Philip Van Kerrebroeck
, et al.
·
European Urology
·
243
Efficacy, Safety and Tolerability of Fesoterodine for Overactive Bladder Syndrome
2007
·
Victor W. Nitti
, Roger Dmochowski
, et al.
·
The Journal of Urology
·
187
Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxina in a randomized, placebo‐controlled dose‐finding study in idiopathic overactive bladder
2011
·
Eric Rovner
, Michael Kennelly
, et al.
·
Neurourology and Urodynamics
·
180
A Randomized Double-blind Placebo-controlled Phase 2 Dose-ranging Study of OnabotulinumtoxinA in Men with Benign Prostatic Hyperplasia
2012
·
Michael Marberger
, Emmanuel Chartier-Kastler
, et al.
·
European Urology
·
101
OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology
2013
·
David Ginsberg
, Francisco Cruz
, et al.
·
Advances in Therapy
·
93
PDF
Long-term Efficacy and Safety of OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity: An Interim Analysis
2013
·
Michael Kennelly
, Roger Dmochowski
, et al.
·
Urology
·
85
PDF
Onabotulinumtoxin A improves urodynamic outcomes in patients with neurogenic detrusor overactivity
2013
·
Eric Rovner
, Roger Dmochowski
, et al.
·
Neurourology and Urodynamics
·
82
PDF
Validation of Treatment Benefit Scale for Assessing Subjective Outcomes in Treatment of Overactive Bladder
2008
·
S. Colman
, C. Chapple
, et al.
·
Urology
·
72
A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of OnabotulinumtoxinA 200 U to Treat Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia
2014
·
Kevin T. McVary
, Claus G. Roehrborn
, et al.
·
The Journal of Urology
·
46
Corrigendum to: “Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder” [Eur Urol 2007;52:1204–12]
2008
·
Christopher Chapple
, Philip Van Kerrebroeck
, et al.
·
European Urology
·
44
Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
2023
·
Victor Nitti
, Cornelia Haag-Molkenteller
, et al.
·
Medicine
·
36
Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)
2023
·
Alberto L. Epstein
, Cornelia Haag-Molkenteller
·
Cell
·
20
PDF
Pharmacokinetics and Safety of Vibegron 75 mg Administered as an Intact or Crushed Tablet in Healthy Adults
2022
·
Jennifer King
, Ann Walker
, et al.
·
Clinical Pharmacology in Drug Development
·
19
PDF
Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial
2021
·
Michael A. Weber
, Cornelia Haag-Molkenteller
, et al.
·
Blood Pressure Monitoring
·
17
Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial.
2022
·
Michael A Weber
, Cornelia Haag-Molkenteller
, et al.
·
PubMed Central
·
12
PDF
Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder
2023
·
Roger R. Dmochowski
, Eric S. Rovner
, et al.
·
BMC Urology
·
9
PDF
Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial
2022
·
Diane K. Newman
, Elizabeth Thomas
, et al.
·
Urogynecology
·
8
1515 Phase 3 Efficacy and Safety Study of Onabotulinumtoxina in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
2011
·
David Ginsberg
, Angelo Gousse
, et al.
·
The Journal of Urology
·
6
Show more works
View as search
Works count:
54
Citation count:
4,163
H-index:
19
I10-index:
22
Year
Topic
Type